TY - JOUR
AR - COR-2019-5-104
TI - Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report
AU - El Ali, Ziad
AU - Verset, Laurine
JO - Clinical Oncology and Research
PY - 2019
DA - Thu 24, Oct 2019
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2019.05.04
UR - https://www.sciencerepository.org/budosenid-treatment-of-avelumab-induced-autoimmune-colitis-in-patient-with-metastatic-merkel-cell-carcinoma_COR-2019-5-104 
KW - Oral budesonid, avelumab, autoimmune colitis
AB - Merkel cell carcinoma is a rare and highly agressive primary cutaneous cancer with epithelial and neuroendocrine features. Currently, for stage IV disease, up-front immunotherapy with check-point inhibitors, anti PD-L1 and anti PD-1, is recommanded. We report the case of a patient who was treated with Avelumab for a metastatic Merkel cell carcinoma. He presented a treatment induced grade II immune colitis, treated successfully with oral Budesonid, a synthetic steroid with high topical anti-inflammatory activity, minimal systemic absorption, and fewer side effects.